In Vitro Activity of New β-Lactamase Inhibitor Combinations against blaNDM, blaKPC, and ESBL-Producing Enterobacteriales Uropathogens

• Published in: Antibiotics (Basel) Vol. 12; no. 10; p. 1481
• Main Authors: Razaq, Lubna, Uddin, Fakhur, Ali, Shahzad, Abbasi, Shah Muhammad, Sohail, Muhammad, Yousif, Nabila E., Abo-Dief, Hala M., El-Bahy, Zeinhom M.
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 25.09.2023; MDPI
• Subjects: Amides; Antibiotic resistance; Antibiotics; Antimicrobial agents; Antimicrobial resistance; Bacteria; Bacterial infections; Carbapenemase; Ceftazidime; ceftazidime/avibactam; Cephalosporins; Chromium; Drug resistance; E coli; Genes; Inhibitors; Klebsiella pneumoniae carbapenemase; Meropenem; meropenem/vaborbactam; Metallo-β-lactamase; Metallography; Mortality; New Delhi metallo-β-lactamase; Pathogens; Plasmids; Tazobactam; Urinary tract; Urinary tract infections; β-Lactam antibiotics; United States > US

Antibiotic resistance in uropathogens has increased substantially and severely affected treatment of urinary tract infections (UTIs). Lately, some new formulations, including meropenem/vaborbactam (MEV), ceftazidime/avibactam (CZA), and ceftolozane/tazobactam (C/T) have been introduced to treat infe...